last
decad
applic
qualit
quantit
nucleic
acid
detect
techniqu
major
impact
diagnost
clinic
virolog
signal
target
amplificationbas
system
current
use
routin
virolog
laboratori
howev
commerci
assay
avail
limit
number
target
result
develop
introduct
assay
develop
inhous
viral
target
improv
autom
nucleic
acid
sampl
isol
techniqu
well
realtim
detect
method
new
gener
assay
clinic
import
virus
develop
technolog
improv
also
make
possibl
gener
result
short
turnaround
time
exampl
individualpati
diseasemanag
concept
introduc
clinic
set
quantit
detect
epsteinbarr
viru
ebv
tcelldeplet
allogen
stem
cell
transplant
patient
enabl
us
develop
model
preemptiv
antibcel
immunotherapi
ebv
reactiv
reduc
incid
ebv
lymphoprolif
diseas
ebvlpd
virusrel
mortal
also
feasibl
introduc
molecular
test
virus
easili
detect
use
classic
virolog
method
cultur
techniqu
antigen
detect
prospect
studi
need
evalu
clinic
import
addit
posit
sampl
detect
howev
clear
complet
exchang
technolog
unlik
occur
complementari
method
stay
oper
make
possibl
discoveri
new
virus
furthermor
abil
characteris
virus
easili
sequenc
open
new
possibl
epidemiolog
studi
also
urgent
need
regard
molecular
diagnost
method
introduct
use
standardis
materi
particip
intern
qualiti
control
programm
final
introduct
univers
intern
control
throughout
whole
procedur
accuraci
result
gener
warrant
advanc
made
last
decad
make
possibl
sensit
detect
characteris
viral
nucleic
acid
amplif
method
pcr
nucleic
acid
sequencebas
amplif
nasba
princip
make
possibl
amplif
target
interest
technolog
improv
sequenc
detect
system
make
possibl
characteris
viru
fulli
determin
instanc
subtyp
genotyp
variant
mutant
genotyp
resist
pattern
introduct
nucleic
acid
method
routin
diagnost
repres
great
step
forward
introduct
realtim
method
detect
amplifi
product
easili
overview
see
mackay
et
al
niester
method
abl
quantifi
target
nucleic
acid
singl
sampl
larger
dynam
rang
quantit
method
although
qualit
detect
cours
also
possibl
sinc
amplif
detect
current
perform
automat
labourintens
critic
step
remain
effici
extract
nucleic
acid
differ
clinic
sampl
second
advanc
clinic
virolog
increas
number
antivir
strategi
avail
commerci
interest
virus
hiv
hepat
b
viru
hbv
hepat
c
viru
hcv
also
gener
virus
epsteinbarr
viru
ebv
enterovirus
new
antivir
howev
use
success
combin
optim
diagnost
strategi
employ
diseasemanag
context
integr
approach
combin
diagnost
treatment
still
sever
problem
must
solv
molecular
diagnost
routin
implement
tabl
first
recognis
commerci
standardis
assay
clinic
laboratori
avail
limit
number
target
mainli
hiv
type
hbv
hcv
limit
extent
cytomegaloviru
cmv
human
papilloma
viru
unlik
number
target
virus
increas
rapidli
near
futur
howev
emphasis
larg
grow
list
virus
implement
use
nucleic
acid
method
advantag
tabl
tent
list
commerci
interest
virus
vs
viral
target
limit
commerci
interest
given
second
bottleneck
easi
reproduc
isol
nucleic
acid
rna
dna
sever
clinic
specimen
fulli
autom
system
high
reliabl
essenti
success
implement
nucleic
acid
detect
daytoday
clinic
virolog
set
enabl
laboratori
gener
result
short
turnaround
time
essenti
diseas
manag
third
bottleneck
concern
standardis
qualiti
control
programm
known
sinc
earli
one
greatest
problem
overcom
molecular
method
fals
posit
caus
contamin
fals
neg
associ
great
differ
sensit
case
homebrew
assay
furthermor
difficulti
detect
genotyp
exampl
hcv
equal
amplif
effici
also
report
programm
within
europ
initi
inde
shown
need
obtain
standardis
materi
need
particip
programm
successor
one
initi
call
qcmd
qualiti
control
molecular
diagnost
http
www
qcmdorg
endors
european
societi
clinic
virolog
escv
european
societi
clinic
microbiolog
infecti
diseas
escmid
start
provid
qualiti
control
programm
increas
number
viral
target
whether
commerci
interest
besid
need
welldefin
qualiti
control
programm
still
lack
standardis
quantit
assay
mainli
standardis
limit
select
number
bloodborn
virus
hbv
hcv
intern
accept
standard
avail
standard
unfortun
singl
viral
genotyp
subtyp
case
focus
specif
blood
bank
screen
routin
virolog
diagnost
one
problem
must
solv
develop
assay
noncommerci
interest
viral
target
introduc
magnapur
lc
system
roch
appli
scienc
penzberg
germani
laboratori
open
extract
system
initi
extract
rna
dna
serum
plasma
combin
realtim
detect
whether
taqman
technolog
nasba
amplif
enabl
us
extract
automat
subsequ
detect
rna
dna
larg
dynam
rang
singl
clinic
sampl
monitor
extract
process
loss
inhibit
introduc
use
univers
intern
viral
control
consist
complet
nonhuman
seal
herpesviru
dna
viru
phhv
type
realtim
quantit
taqman
assay
develop
seal
herpesviru
grown
rel
easili
cell
cultur
assumpt
viru
use
univers
control
behav
similarli
extract
procedur
target
viru
interest
would
exampl
plasmid
use
intern
control
low
fix
amount
viru
equal
amount
give
cycl
threshold
valu
realtim
assay
c
depend
lot
number
use
ad
clinic
sampl
case
mostli
serum
plasma
extract
procedur
start
viru
coextract
subsequ
amplifi
quantit
manner
still
separ
tube
method
monitor
combin
effect
extract
loss
sampl
amplif
inhibit
enabl
us
confid
quantit
result
gener
viral
target
interest
addit
neg
result
clinic
sampl
better
target
detect
therefor
gener
high
confid
data
intern
control
routin
import
spreadsheet
program
defin
threshold
approv
reject
final
result
typic
exampl
shown
fig
current
multiplex
clinic
sampl
intern
control
develop
strategi
furthermor
enabl
us
monitor
everi
new
approach
equip
techniqu
extract
rapidli
enabl
us
check
whether
differ
lot
number
reagent
behav
ident
extern
standard
also
less
ident
sampl
interest
similar
amplif
effici
clinic
sampl
matrix
extern
control
extract
extract
similar
sampl
interest
impli
clone
materi
extern
control
might
problemat
problem
standard
intern
standard
alreadi
address
conclus
absolut
quantif
hard
achiev
especi
viral
target
would
classifi
present
commerci
interest
intern
collabor
diagnost
laboratori
take
lead
enabl
us
tackl
problem
cours
exclud
use
realtim
method
quantifi
viral
target
sinc
shown
give
invalu
niester
molecular
diagnost
virolog
real
time
inform
virus
host
interact
recent
develop
realtim
method
detect
amplif
product
gener
pcr
nasba
method
quantif
rna
dna
clinic
sampl
made
much
easier
also
avail
readytogo
reagent
rt
pcr
nasba
step
forward
numer
exampl
detect
quantif
viral
target
publish
alreadi
overview
see
niester
list
grow
rapidli
whole
process
isol
detect
autom
target
optim
strategi
still
need
establish
determin
threshold
valu
clinic
import
detect
level
need
reach
assay
involv
develop
preemptiv
strategi
reduc
incid
ebv
reactiv
develop
ebvrel
lymphoma
known
posttranspl
lymphoprolif
diseas
ptld
allogen
tcelldeplet
stem
cell
transplant
patient
taqmanbas
assay
gene
encod
bnrf
protein
develop
use
investig
incid
ebv
reactiv
develop
ebvrel
ptld
moreov
assay
perform
frequent
current
five
time
week
enabl
us
determin
kinet
ebv
replic
patient
popul
sever
conclus
could
drawn
one
stepwis
increas
ebv
dna
measur
plasma
yield
hazard
ratio
confid
interv
develop
ptld
patient
receiv
tcelldeplet
graft
p
furthermor
shown
patient
receiv
antithymocyt
globulin
atg
part
condit
regimen
belong
popul
highest
risk
tcell
deplet
determin
problem
find
viral
load
one
interven
preemptiv
antivir
strategi
ie
identifi
precis
patient
risk
threshold
copi
ml
plasma
chosen
indic
start
treatment
rituximab
monoclon
antibodi
direct
receptor
bind
site
ebv
although
result
overtreat
patient
experienc
ebv
reactiv
like
would
develop
ebv
ptld
reduct
ebv
ptld
incid
complet
abrog
ptld
mortal
month
observ
exampl
kinet
pattern
observ
ebv
dna
measur
plasma
shown
fig
seen
ebv
dna
viral
load
increas
rapidli
make
necessari
perform
realtim
test
regular
basi
monitor
patient
risk
followup
initi
treatment
thu
frequent
necessari
strategi
monitor
patient
risk
also
use
success
cytomegaloviru
cmv
viral
load
kinet
pattern
use
identifi
patient
like
recurr
cmv
diseas
initi
antivir
therapi
well
identifi
patient
treat
sampl
number
ct
valu
fig
data
c
valu
amplif
plot
seal
herp
viru
type
ad
fix
concentr
approxim
copi
ml
clinic
sampl
result
singl
experi
shown
import
spreadsheet
viru
coextract
use
magnapur
lc
isol
station
quantifi
sequenc
detect
system
use
taqman
univers
reaction
mixtur
appli
biosystem
nieuwerkerk
aan
de
ijssel
netherland
primer
probe
sequenc
forward
primer
revers
primer
probe
label
tet
amplif
product
bp
within
gb
gene
gener
averag
c
valu
averag
sampl
analys
lot
number
sd
sampl
c
valu
intern
control
averag
plu
sd
repeat
one
run
see
arrow
abl
detect
quantifi
princip
viru
interest
question
remain
whether
precis
characteris
isol
detect
viru
necessari
patient
manag
bloodborn
virus
characteris
viru
becom
less
routin
practic
clinic
virolog
hiv
genotyp
resist
pattern
usual
obtain
sequenc
revers
transcriptas
proteas
gene
gener
much
inform
determin
optim
antiretrovir
therapi
use
mostli
combin
quantit
rna
data
hcv
genotyp
import
combin
viral
load
determin
durat
therapi
use
interferon
ribavirin
also
hbv
accumul
data
indic
relationship
genotyp
success
antivir
treatment
sequenc
principl
ultim
method
characteris
disadvantag
howev
antivir
treatment
mixtur
wildtyp
variant
viru
exist
observ
sequenc
suitabl
detect
minor
popul
variant
virus
method
revers
hybridis
restrict
fragment
length
polymorph
analysi
might
suitabl
clear
success
sequenc
chang
specif
gene
known
viral
load
measur
help
search
new
variant
antivir
treatment
recent
describ
discoveri
new
hbv
variant
resist
lamivudin
sequenc
technolog
implement
laboratori
set
question
whether
use
characteris
viral
target
serotyp
current
use
alreadi
shown
sequenc
success
characteris
enterovirus
rhinovirus
result
compar
obtain
serotyp
implement
molecular
method
result
improv
diagnost
number
virus
use
quantit
detect
nucleic
acid
monitor
antivir
therapi
especi
hbv
hcv
also
develop
amplif
assay
almost
everi
human
viru
includ
virus
cultur
rel
easili
eg
herpesvirus
hsv
type
new
molecular
method
sever
advantag
especi
set
routin
viru
cultur
avail
howev
also
note
improv
sensit
viru
cultur
observ
almost
instanc
introduct
molecular
diagnost
routin
clinic
diagnost
virolog
proceed
rapidli
ultim
replac
reduc
use
viru
cultur
techniqu
implement
autom
extract
detect
method
combin
extens
qualiti
control
programm
ultim
convinc
clinician
virologist
molecular
diagnost
import
clinic
virolog
critic
remark
often
made
posit
result
clinic
signific
counter
good
clinic
epidemiolog
inform
combin
quantit
inform
viru
es
present
howev
abil
exclud
viral
infect
monitor
patient
risk
ebv
ptld
ebv
dna
load
measur
regular
basi
level
copi
ml
patient
recal
hospit
pe
therapi
rituximab
therapi
initi
monitor
perform
five
time
week
ebv
dna
level
twice
limit
detect
assay
copi
ml
signal
decreas
rapidli
increas
observ
second
infus
rituximab
infus
donor
lymphocyt
dli
given
see
data
repres
thick
line
initi
pe
therapi
repres
day
line
repres
individu
patient
advantag
unnecessari
therapeut
option
implement
wrong
antivir
antibiot
inevit
reduc
overal
cost
patient
care
howev
financi
figur
need
prove
thu
improv
accuraci
sensit
combin
rapid
turnaround
time
molecular
techniqu
import
patient
care
provid
inform
guid
best
therapeut
option
cours
still
need
viru
cultur
otherwis
unabl
identifi
new
virus
circul
recent
describ
human
metapneumoviru
clear
major
transit
viru
cultur
molecular
diagnost
hand
avail
open
technolog
isol
amplifi
nucleic
acid
make
possibl
routin
isol
nucleic
acid
increas
rang
clinic
materi
also
use
realtim
detect
system
whole
process
semiautomat
quantit
detect
viral
rna
dna
target
furthermor
risk
contamin
minimis
turnaround
time
gener
result
minim
handl
personnel
whether
posit
neg
becom
shorter
result
gener
easili
within
work
day
expect
near
futur
reduc
hour
molecular
techniqu
becom
part
routin
clinic
virolog
homebrew
assay
matur
sinc
standardis
reagent
improv
qualiti
control
programm
enhanc
laboratori
perform
importantli
standardis
reagent
get
cheaper
make
discuss
concern
high
cost
obsolet
one
greatest
advantag
howev
abil
detect
posit
target
sequenc
clinic
sampl
give
us
insight
relationship
viru
host
importantli
also
allow
patient
risk
treat
specif
molecular
test
success
area
convent
virolog
techniqu
exist
could
improv
current
molecular
test
also
avail
target
convent
technolog
avail
logist
within
laboratori
price
assay
clinic
benefit
new
criteria
make
technolog
improv
fundament
part
new
era
diagnost
set
